We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Characteristic Chemical Signature Identified for Chronic Fatigue Syndrome

By LabMedica International staff writers
Posted on 15 Sep 2016
Chronic fatigue syndrome (CFS) is a multisystem disease that causes long-term pain and disability and it is difficult to diagnose because of its protean symptoms and the lack of a diagnostic laboratory test.

The disease is characterized by profound fatigue and disability lasting for at least six months, episodes of cognitive dysfunction, sleep disturbance, autonomic abnormalities, chronic or intermittent pain syndromes, microbiome abnormalities, cerebral cytokine dysregulation, natural killer cell dysfunction, and other symptoms that are made worse by exertion of any kind.

Scientists at the University Of California San Diego School Of Medicine (San Diego, CA, USA) recruited prospectively patients and controls to their study over a one-year period. More...
Healthy controls were age- and sex-matched volunteers without CFS. The total number of subjects analyzed in this study was 84. This included 23 females and 22 males with CFS and 18 male and 21 female controls.

Targeted, broad-spectrum, chemometric analysis was performed for 612 metabolites from 63 biochemical pathways by hydrophilic interaction liquid chromatography, electrospray ionization, and tandem mass spectrometry in a single-injection method. Samples were analyzed on an AB SCIEX QTRAP 5500 triple quadrupole mass spectrometer (AB SCIEX, Framingham, MA, USA) equipped with a Turbo V electrospray ionization (ESI) source, Shimadzu LC-20A UHPLC system (Shimadzu Corporation, Kyoto, Japan), and a PAL CTC autosampler (CTC Analytics AG, Lake Elmo, MN, USA).

Patients with CFS showed abnormalities in 20 metabolic pathways with 80% of the diagnostic metabolites were decreased, consistent with a hypometabolic syndrome. Pathway abnormalities included sphingolipid, phospholipid, purine, cholesterol, microbiome, pyrroline-5-carboxylate, riboflavin, branch chain amino acid, peroxisomal, and mitochondrial metabolism. The diagnostic accuracy rate exceeded 90%. Area under the receiver operator characteristic curve analysis showed diagnostic accuracies of 94% in males using eight metabolites and 96% in females using 13 metabolites.

Robert K. Naviaux, MD, PhD, professor of medicine, pediatrics and pathology and first author of the study said, “CFS is a very challenging disease. It affects multiple systems of the body. Symptoms vary and are common to many other diseases. There is no diagnostic laboratory test. Patients may spend tens of thousands of dollars and years trying to get a correct diagnosis. Despite the heterogeneity of CFS, the diversity of factors that lead to this condition, our findings show that the cellular metabolic response is the same in patients.” The study was published on August 29, 2016, in the journal Proceedings of the National Academy of Sciences of the United States of America.

Related Links:
University Of California San Diego
AB SCIEX
Shimadzu
CTC Analytics


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.